| Heidi Lopez-coonjohn, MD | |
|
3260 Hospital Dr, Juneau, AK 99801 | |
| (907) 796-8632 | |
| Not Available |
| Full Name | Heidi Lopez-coonjohn |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 3260 Hospital Dr, Juneau, Alaska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679581508 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | MD5755 (Alaska) | Primary |
| Entity Name | Bartlett Regional Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154331734 PECOS PAC ID: 7517950868 Enrollment ID: O20040405000593 |
News Archive
When Garnett and Dave Mellen sent their 19-year-old daughter, Gita, off to college an hour away at Virginia Commonwealth University last fall, they didn't expect to follow her.
Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).
Researchers at the Johns Hopkins Bloomberg School of Public Health have identified a bacterium in field-caught mosquitoes that, when present, stops the development of Plasmodium falciparum, the parasite that causes malaria in humans.
Hydrocephalus in Ugandan children and other developing countries is seasonal, linked to farm animals and in part, caused by previous bacterial infection, according to an international team of researchers from Uganda and the United States, who believe that the best approach to this problem is prevention.
More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide which to prescribe.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heidi Lopez-coonjohn, MD 3260 Hospital Dr, Juneau, AK 99801 Ph: () - | Heidi Lopez-coonjohn, MD 3260 Hospital Dr, Juneau, AK 99801 Ph: (907) 796-8632 |
News Archive
When Garnett and Dave Mellen sent their 19-year-old daughter, Gita, off to college an hour away at Virginia Commonwealth University last fall, they didn't expect to follow her.
Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).
Researchers at the Johns Hopkins Bloomberg School of Public Health have identified a bacterium in field-caught mosquitoes that, when present, stops the development of Plasmodium falciparum, the parasite that causes malaria in humans.
Hydrocephalus in Ugandan children and other developing countries is seasonal, linked to farm animals and in part, caused by previous bacterial infection, according to an international team of researchers from Uganda and the United States, who believe that the best approach to this problem is prevention.
More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide which to prescribe.
› Verified 5 days ago
Robert D Schults, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8498 Fax: 907-796-8497 | |
Dr. David Benjamin Robinson, M.D., M.P.H. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2239 Jordan Ave, Juneau, AK 99801 Phone: 907-789-3800 Fax: 907-789-2402 | |
Marie Roy Babbitt, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3240 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8948 Fax: 907-796-8497 | |
Mr. Paul Jiri Topol, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2 Marine Way, Suite 204, Juneau, AK 99801 Phone: 907-209-8962 Fax: 866-581-8172 | |
Dr. Susan E Hunter-joerns, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2205 Jordan Ave, Juneau, AK 99801 Phone: 907-790-3224 Fax: 907-790-3226 | |
Dr. Eli Alexander Woods Oates, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8900 | |
Alvin J Fineman, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3240 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8498 Fax: 907-796-8497 |